Grifols Names Two New Directors in Win for Hedge Fund Mason
- Drugmaker says Ravery, Herendeen to fill vacant board seats
- Herendeen had been proposed by group of investors led by Mason
This article is for subscribers only.
Grifols SA, the drugmaker reeling from a short-seller attack earlier this year, named two new board members as it faces pressure from a group of small shareholders led by hedge fund Mason Capital Management LLC.
Grifols will appoint Pascal Ravery, a former executive at Goldman Sachs Group Inc. and JPMorgan Chase & Co., and Paul S. Herendeen, who has served as an executive at several health firms, to fill two vacant seats on the board, the Spanish company said in a filing late Monday.